Trials / Completed

CompletedNCT03573323

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 1,027 (actual)

Sponsor: Eli Lilly and Company · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

Conditions

Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Ixekizumab	Administered SC
DRUG	Guselkumab	Administered SC
DRUG	Placebo	Administered SC

Timeline

Start date: 2018-11-09
Primary completion: 2019-07-15
Completion: 2020-01-08
First posted: 2018-06-29
Last updated: 2020-07-28
Results posted: 2020-07-28

Locations

124 sites across 3 countries: United States, Canada, Puerto Rico

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT03573323. Inclusion in this directory is not an endorsement.